Sprionaloctone

NHS England has published this Preliminary Market Engagement Notice for the Licence variation: spironolactone for acne in women. It is anticipated that there will be two separate contracts to deliver this, as outlined below. • Contract A: Prepare an application for a major (type II) MHRA Marketing Authorisation variation for spironolactone. • Contract B: Submit the pre-prepared application to the MHRA. Only current Marketing Authorisation Holders of spironolactone are eligible to bid for contract B. To register an...